

**ASX ANNOUNCEMENT**

**CELLMID INVESTOR BRIEFING**

**SYDNEY, Tuesday, 23 February 2016: Cellmid Limited (ASX: CDY)** is pleased to advise that it has made significant progress towards its revenue target of \$4 million for the Consolidated Entity for the year ending 30 June 2016.

**Cellmid will be hosting a conference call to brief the market on its operations, sales results and distribution channels on Thursday, 25 February 2016 at 1:00pm (AEDT).**

The Appendix 4D for the Consolidated Entity with the audited Interim Financial Report for the six months ending 31 December 2015 is expected to be available prior to the briefing.

Cellmid CEO, Maria Halasz, will be discussing operations, marketing and sales activities in Australia and Japan, and will outline developments in the Consolidated Entity's international distribution strategy in major markets for the second half of FY2016 and beyond.

To join the conference call, please dial via the numbers below shortly before the scheduled timeslot. **Conference ID: 306 438** – please provide this ID when joining the call.

Australian participant dial-in numbers:

Local: **+61 2 9007 8048**  
Alt. Local: **+61 7 3145 4005**

International participant dial-in numbers:

USA/Canada Toll Free: **1855 624 0077**  
UK Toll Free: **0800 051 1453**  
Japan Toll Free: **0066 3386 8000**  
Hong Kong Toll Free: **800 968 273**  
Singapore Toll Free: **800 101 2702**

For countries not listed, please dial the Australian participant local number listed above. To ask a question during the live Q&A session, participants will need to **press \* (star) followed by 1 (\*, 1)** on their telephone keypad to enter the Q&A queue.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

## **Cellmid Limited (ASX: CDY)**

Cellmid is an Australian life sciences company with lead programmes in multiple disease indications. The Company is developing innovative novel therapies and diagnostic tests for cancer and inflammatory diseases. Through its wholly owned subsidiaries, Advangen Limited and Advangen Inc., Cellmid also develops and sells FGF5 inhibitor hair loss products. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see [www.cellmid.com.au](http://www.cellmid.com.au) and [www.evolisproducts.com.au](http://www.evolisproducts.com.au).

## **Advangen Limited and hair growth products**

Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of anti-aging hair care products. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, China and Taiwan. Concurrently, Advangen has been developing midkine, a growth factor, for hair loss utilising its anti-apoptotic effects. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes.

## **Midkine (MK)**

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is highly anti-apoptotic protecting cells from dying. It is this mechanism of action that is thought to be responsible for midkine's ability to regenerate hair growth in various models of the condition.